GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.


Immunotherapy Forum Video #6: In Part 2 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.


Immunotherapy Forum Video #5: In Part 1 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.


There were many advances in lung cancer targeted treatments in 2014. The one that most excites Dr. Geoffrey Oxnard from Dana-Farber Cancer Institute is the use of liquid biopsies.


Immunotherapy Forum Video #4: In Part 2 of 2 videos on this topic, Dr. Matthew Hellmann from the Memorial Sloan Kettering Cancer Center discusses the century-long history of attempting to treat cancer with immunotherapy.


Immunotherapy Forum Video #3: In Part 1 of 2 videos on this topic, Dr. Matthew Hellmann from the Memorial Sloan Kettering Cancer Center discusses the century-long history of attempting to treat cancer with immunotherapy.


Immunotherapy Forum Video #2: In Part 2 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.


Immunotherapy Forum Video #1: In Part 1 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.


Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, gives thanks to GRACE this week and urges others to do the same.

Direct download: GRACEcast-292_Lung-Video_LCAM_Duff_Dose_of_Hope_Annual_Appeal.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, shares her journey from stunned patient to empowered patient.


Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.


November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jared Weiss, GRACE Vice President, and his patient Tomma Hargraves, discuss how they became a team.


Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.


Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.


November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jack West, GRACE founder and president, explains the steps that patients can do become empowered.


Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.


Acquired Resistance Forum Video #11: Bonnie J. Addario, founder of the Addario Lung Cancer Foundation described how the lung cancer community can work together to support each other and affect change for all patients.


Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

Direct download: GRACEcast-283_Lung-Video_AR_Forum_Q_A_Doebele_Shaw_Uthe.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.

Direct download: GRACEcast-282_Lung-Video_AR_Forum_New_ALK_ROS1_Approaches.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.


Acquired Resistance Forum Video #7: Speakers from videos #5 and #6 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.

Direct download: GRACEcast-280_Lung-Video_AR_Forum_Q_A_Blumenthal_Pennell_West.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.


Acquired Resistance Forum Video #5: Dr. Gideon Blumenthal of the US Food and Drug Administration (FDA) discussed the FDA process for approving targeted therapies.


Acquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West. 


Acquired Resistance Forum Video #3: Dr. Lecia Sequist of Massachusetts General Hospital detailed why doctors started doing repeat biopsies for patients receiving targeted therapies and how they help patients and doctors determine next steps in treatment.


Acquired Resistance Forum Video #2: Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients' options are when their ALK, ROS1 or EGFR lung cancer progresses. September 2014


Acquired Resistance Forum Video #1: Dr. Gregory J. Riely of Memoral Sloan Kettering Cancer Center opened the Acquired Resistance in Lung Cancer Patient Forum with a basic introduction of how ALK, ROS1 and EGFR lung cancers become resistant to treatment. September 2014


Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014


Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014


For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014


For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014


Eighty percent of lung cancer patients have wild type EGFR, meaning there is no EGFR mutation. Dr. Joan Schiller of UT Southwestern Medical Center discusses a new drug in development that may help those patients. February 2014


The stigma of lung cancer can lead to shame, fear, and sub-optimal care. Dr. Joan Schiller wants us all to get past it, and she's leading the charge to make that happen. February 2014.


Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014


Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.


A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.


Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014

Direct download: GRACEcast-264_Lung-Video_IASLC_Morgensztern_LC_Fight_Optimism.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014


HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.


Leptomeningeal carcinomatosis is cancer that has spread to the coating of the brain and spinal cord. In the past, prognosis has been bad. But now doctors are learning of effective treatments to deal with this issue.

Direct download: GRACEcast-232_Lung-Video_IASLC_Riess_Treating_LMC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor mutations, rather than where the tumor began. Dr. Melissa Johnson describes the work of the center.


Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow.


Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.


Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient's cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning.


Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.


Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.


Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.

Direct download: GRACEcast-258_Lung-Video_ASCO_2014_Immunotherapy_Since_2013.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Daniel Heng has advice to kidney cancer patients who want the best treatment for their disease. To find a clinical trial that is right for you, visit clinicaltrials.gov and enter "kidney cancer" in the search box.


Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Eroltinib for early-stage lung cancer.


Predictive biomarkers can indicate if a patient will respond to a particular therapy. Dr. Lauren Harshman discusses if researchers know of any biomarkers for kidney cancer patients taking PD1 inhibitor drugs.


Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.


What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.


The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.


NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.


Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

Direct download: GRACEcast-250_Lung-Video_ASCO_2014_Necitumumab_Squamous_LC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.


The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.


Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.


The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.


Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.


"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).


Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.


Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.


Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.


Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.


Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.


Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

Direct download: GRACEcast-229_Lung-Video_IASLC_Riess_FGFR_Role_Squamous_LC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

Direct download: GRACEcast-237_Lung-Video_ASCO_2014_AZD9291_Resistance_EGFR.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.

Direct download: GRACEcast-228_Lung-Video_IASLC_Johnson_HSP90_Inhibitors.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.


Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.


An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.


Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?


A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.


Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.

Direct download: GRACEcast-234_Lung-Video_ASCO_2014_Avastin_Tarceva_Help_EGFR.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.

Direct download: GRACEcast-225_Lung-Video_IASLC_Neal_FGFR_Valuable_Target.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.


Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.

Direct download: GRACEcast-223_Lung-Video_IASLC_Goldman_New_Drug_TH-302.mp4
Category:Lung-Cancer-Video -- posted at: 2:47pm PDT

How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.

Direct download: GRACEcast-222_Lung-Video_IASLC_Riess_Broad_LC_Tumor_Testing.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.


When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.

Direct download: GRACEcast-220_Lung-Video_IASLC_Neal_Wild_Type_EGFR_Genes.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.

Direct download: GRACEcast-219_Lung-Video_IASLC_Goldman_Teaching_Immune_System.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they have and which, if any, mutations their lung tumors may have. He explains why in this video.

Direct download: GRACEcast-218_Lung-Video_IASLC_Riess_Know_About_Your_Disease.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT

If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.


Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.


Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.


Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.


Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on those therapies after their cancers begin to grow again. February 2014.


Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.


Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.


Dr. Cathy Pietanza of Memorial Sloan Kettering explains how small cell lung cancer and non-small cell lung cancer are differentiated. February 2014.


Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014.


Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors without invasive biopsies. February 2014.


Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.


Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.


Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.


Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.


Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. February 2014.


Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.


Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.